Oral Candida isolates among HIV-infected subjects in Nigeria

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 3, 2011, Pages 172-177

  Nweze, Emeka Innocent ^a   Ogbonnaya, Ulu Lawrence ^b  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b EBONYI STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

Antifungal susceptibility; Antiretroviral therapy; HIV patients; Nigeria; Oral Candida; Yeast

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VORICONAZOLE; ZIDOVUDINE;

ADULT; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FEMALE; FUNGAL COLONIZATION; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NIGERIA; THRUSH;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; NIGERIA; PYRIMIDINES; TRIAZOLES;

EID: 79955083472     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.01.028     Document Type: Article

References (25)

1. Brawnier D.L., Hovan A.J. Oral candidiasis in HIV-infected patients. Curr Top Med Mycol 1995, 6:113-125.
2. Dupont B., Denning D.W., Marriot D., Sugar A., Viviani M.A., Sirisanthana T. Mycosis and AIDS patients. J Med Vet Mycol 1994, 32:65-77.
3. Barchiesi F., Maracci M., Radi B., Arzeni D., Baldassarri I., Giacometti A., et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002, 50:999-1002.
4. Gottfredsson M., Cox G.M., Indridason O.S., De Almeida G.M.D., Heald A.E., Perfect J.R. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999, 180:534-537.
5. Costa C.R., de Lemos J.A., Passos X.S., de Araújo C.R., Cohen A.J., Souza L.K., et al. Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia 2006, 162:45-50.
6. Kirkpatrick W.R., Revankar S.G., Mcatee R.K., Lopez-Ribot J.L., Fothergill A.W., McCarthy D.L., et al. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 1998, 36:3007-3012.
7. UNAIDS 2006 Report on the global AIDS epidemic: overview of the global AIDS epidemic Available at, [Accessed August 2, 2007]. http://data.unaids.org/pub/EpiReport/2006/04-Sub_Saharan_Africa_2006_EpiUpdate_eng.pdf.
8. Federal Ministry of Health Nigeria 2005 National HIV/syphilis seroprevalence sentinel survey among pregnant women attending antenatal clinics: technical report, April 2006, Federal Ministry of Health, Abuja, Nigeria.
9. Chima Oji, Chukwuneke F. Evaluation and treatment of oral candidiasis in HIV/AIDS patients in Enugu, Nigeria. Oral Maxillofac Surg 2008, 12:67-71.
10. Anteyi Kate O, Thacher Tom D, Yohanna Stephen, Idoko John I Oral manifestations of HIV-AIDS in Nigerian patients. Int J STD AIDS 2003, 14:395-398.
11. Enwuru C.A., Ogunledun A., Idika N., Enwuru N.V., Ogbonna F., Aniedobe M., et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008, 8:142-148.
12. Nweze E.I., Okafor J.I. Prevalence of dermatological fungal infections in children: A recent study in Anambra State, Nigeria. Mycopathologia 2005, 160:239-243.
13. Nweze E.I. Dermatophytosis in Western Africa: A review. Pak J Biol Sci 2010, 13:649-656.
14. Colombo A.L., Da Matta D., De Almeida L.P., Rosas R. Fluconazole susceptibility of Brazilian Candida isolates assessed by a disk diffusion method. J Infect Dis 2002, 6:118-123.
15. Sojakova M., Liptajova D., Borovsky M., Subik J. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 2004, 157:163-169.
16. Kurtzman C.P., Fell J.W. The yeasts: a taxonomic study 1998, Elsevier, Amsterdam, The Netherlands, 77-100. 4th ed.
17. Tekeli A., Koyuncu E., Dolapaci I., Guven G.S., Sahin G.O., Uzin O. Detection of Candida dubliniensis in oropharyngeal samples of Turkish HIV-positive patients. Mycoses 2005, 48:197-201.
18. CLSI-Clinical Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. Document M27-A2 2002, vol. 17. CLSI, Villanova, PA, n. 9.
19. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., Hollis R.J. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E-test methods: report from the ARTEMIS Global Antifungal Susceptibility Program. J Clin Microbiol 2001, 2003:1440-1446.
20. Pfaller M.A., Boyken L., Messer S.A., Tendolkar S., Hollis R.J., Diekema D.J. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol. 2005, 43:5208-5213.
21. Sánchez-Vargas Luis Octavio, Ortiz-López Natalia Guadalupe, Villar María, Moragues María Dolores, Aguirre José Manuel, Cashat-Cruz Miguel, et al. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol 2005, 22:83-92.
22. Melo N.R., Taguchi H., Jorge J., Pedro R.J., Almeida O.P., Fukushinma K., et al. Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz 2004, 99:425-431.
23. Mokaddas Eiman M, Al-Sweih Noura A, Khan Zia U Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007, 56:255-259.
24. Meiller T.F., Jabra-Riszk M.A., Baqui A., Kelley J.I., Meeks V.I., Merz W.G., et al. Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 88:573-580.
25. Nguyen M.H., Chancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R. Do in vitro susceptibility data predict the microbiological response to Amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998, 177:425-430.